Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

被引：0

作者：

Stilgenbauer, Stephan ^{[1
]}

Morschhauser, Franck ^{[2
]}

Wendtner, Clemens-Martin ^{[3
]}

Cartron, Guillaume ^{[4
]}

Hallek, Michael ^{[5
,6
]}

Eichhorst, Barbara ^{[7
]}

Kozloff, Mark F. ^{[8
]}

Giever, Thomas ^{[9
]}

Lozanski, Gerard ^{[10
]}

Jiang, Yanwen ^{[11
]}

Huang, Huang ^{[12
]}

Pignataro, Daniela Soriano ^{[13
]}

Schary, William ^{[14
]}

Humphrey, Kathryn ^{[15
]}

Mobasher, Mehrdad ^{[11
]}

Salles, Gilles ^{[16
]}

机构：

[1] Ulm Univ, Dept Internal Med 3, Ulm, Germany

[2] Univ Lille 2, Ctr Hosp Univ, Hematol, Lille, France

[3] Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[4] Univ Hosp Montpellier, Dept Clin Hematol, Montpellier, France

[5] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[6] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany

[7] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[8] Univ Chicago Med, Chicago, IL USA

[9] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

[10] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] F Hoffmann La Roche Ltd, Mississauga, ON, Canada

[13] Roche Prod Ltd, Welwyn Garden City, Herts, England

[14] AbbVie, N Chicago, IL USA

[15] Roche Prod Ltd, Welwyn Garden City, Herts, England

[16] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, CHU Lyon Sud, Dept Hematol, Pierre Benite, France

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-118362

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1859

引用

页数：5

共 50 条

[31] Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Bosch, Francesc
Illmer, Thomas
Turgut, Mehmet
Cortelezzi, Agostino
Lasserre, Susan F.
Truppel-Hartmann, Anna
Leblond, Veronique
Foa, Robin
Stilgenbauer, Stephan
BLOOD, 2014, 124 (21)
[32] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
Cramer, Paula
Fuerstenau, Moritz
Robrecht, Sandra
Giza, Adam
Fink, Anna
Fischer, Kirsten
Langerbeins, Petra
Al-Sawaf, Othman
Tausch, Eugen
Schneider, Christof
Schetelig, Johannes
Dreger, Peter
Boettcher, Sebastian
Kreuzer, Karl-Anton
Schilhabel, Anke
Brueggemann, Monika
Kneba, Michael
Wendtner, Clemens
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
[33] Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
Danilov, Alexey
Yimer, Habte A.
Boxer, Michael
Burke, John M.
Babu, Sunil
Li, Jia
Mun, Yong
Trask, Peter C.
Masaquel, Anthony S.
Sharman, Jeff P.
BLOOD, 2019, 134
[34] Genomic Alterations and Outcomes With Fixed-Duration Ibrutinib plus Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Kater, Arnon
Hodkinson, Brendan
Moreno, Carol
Munir, Talha
Levin, Mark-David
Niemann, Carsten
Qi, Keqin
Sinet, Pierre
Baeten, Kurt
Caces, Donne Bennett
Srinivasan, Srimathi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S329 - S329
[35] Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
Danilov, Alexey, V
Yimer, Habte A.
Boxer, Michael A.
Burke, John M.
Babu, Sunil
Li, Jia
Mun, Yong
Trask, Peter C.
Masaquel, Anthony S.
Sharman, Jeff P.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02): : 121 - 128
[36] A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Woyach, Jennifer A.
Ruppert, Amy S.
Perez, Gabriela
Booth, Allison M.
Feldman, Diane
Dib, Elie G.
Jatoi, Aminah
Le-Rademacher, Jennifer
Heerema, Nyla A.
Miller, Cecelia
Lozanski, Gerard
Little, Richard F.
Hill, Brian T.
Ding, Wei
Stone, Richard M.
Mandrekar, Sumithra J.
Byrd, John C.
BLOOD, 2021, 138 : 3728 - +
[37] Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy
Stilgenbauer, Stephan
Bosch, Francesc
Leblond, Veronique
Ilhan, Osman
Kisro, Jens
Mahe, Beatrice
Mikuskova, Eva
Osmanov, Dzhelil
Reda, Gianluigi
Tausch, Eugen
Wojtowicz, Marcin
Perretti, Thomas
Van Hoef, Marlies E. H. M.
Foa, Robin
BLOOD, 2019, 134
[38] Updated Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab for Frontline Treatment of Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 6 - 7
[39] PRELIMINARY SAFETY DATA FROM THE PHASE 3B GREEN STUDY OF OBINUTUZUMAB (G) ALONE OR COMBINED WITH CHEMOTHERAPY FOR PREVIOUSLY UNTREATED OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Leblond, V.
Dilhuydy, M. S.
Foa, R.
Knauf, W.
Montillo, M.
Robinson, S.
Stilgenbauer, S.
Gresko, E.
Lasserre, S.
Bosch, F.
HAEMATOLOGICA, 2016, 101 : 149 - 149
[40] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Salles, Gilles A.
Boyd, Thomas E.
Morschhauser, Franck
Wendtner, Clemens-Martin
Hallek, Michael
Eichhorst, Barbara F.
Kozloff, Mark
Cartron, Guillaume
Li, Yan
Hilger, James
Mobasher, Mehrdad
Stilgenbauer, Stephan
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →